TCM
SUPN icon

Teza Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Teza Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-6,660
Closed -$210K – 271
2025
Q2 		$210K Sell
6,660
-45
-0.7% -$1.44K 0.16% 267
2025
Q1 		$220K Buy
6,705
+83
+1% +$2.94K 0.1% 336
2024
Q4 		$239K Sell
6,622
-2,276
-26% -$80.1K 0.04% 405
2024
Q3 		$277K Buy
+8,898
New +$278K 0.03% 495
2021
Q3 		– Sell
-11,299
Closed -$348K – 575
2021
Q2 		$348K Buy
+11,299
New +$346K 0.06% 404
2019
Q4 		– Sell
-30,372
Closed -$835K – 715
2019
Q3 		$835K Buy
+30,372
New +$900K 0.21% 159

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Teza Capital Management's SUPN Position: Q3 2025 in Review

Teza Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2025, closing a stake of 6,660 shares — an estimated $210K sold.

Teza Capital Management first reported a position in SUPN in Q3 2019 and held it in 6 quarters. The position peaked at $835K in Q3 2019. 310 funds tracked by Wall St. Rank hold SUPN as of Q3 2025.

  • Teza Capital Management reported no remaining Supernus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Teza Capital Management sold 6,660 Supernus Pharmaceuticals shares in Q3 2025, an estimated $210K.
  • Teza Capital Management first reported a position in Supernus Pharmaceuticals in Q3 2019 and held it in 6 quarters.
  • Teza Capital Management's Supernus Pharmaceuticals position peaked at $835K in Q3 2019.
  • 310 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2025.

Based on Teza Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.